The founder's statement
HRA
Pharma was created ten years ago with the objective of developing and marketing products / devices respond to a clear-cut medical need but do not trigger interest
from large pharmaceutical companies. This objective was fully met when HRA succeeded in obtaining a market authorization for Norlevo, the first progestin-only
emergency contraceptive pill ever approved in the Western world. Furthermore, Norlevo was the first EC pill to be granted a non-prescription status,
making it broadly accessible.
Making its products available for the poorest has been a corporate commitment of the company's shareholders and management since onset. HRA, in collaboration with international and local NGOs, has thereby participated in a range of actions aimed to promote education on contraception and facilitate access to products in the most remote and poorest parts of the world. The company's latest such project involves supplying Senegal and Niger with donated IUDs and supporting proper training and education of healthcare providers on IUD insertion and use. This program will be extended to other sub-Saharan African countries in the coming months.
Being aware that humanitarian programs should not be restricted to the company's area of business, and because cultural development is a necessity for development, HRA has sponsored an award at the "Rencontres africaines de la photographie" aimed to reward the work of a young African photographer who displays unique talent and a potential for excellence.
André Ulmann - Founder